SYS-CON MEDIA Authors: Jayaram Krishnaswamy, Lori MacVittie, Gilad Parann-Nissany, Unitiv Blog, Bob Gourley

News Feed Item

Jason LaBonte, Ph.D., Joins MedPanel as President

CAMBRIDGE, Mass., Dec. 30, 2013 /PRNewswire/ -- MedPanel, LLC, a firm specializing in providing primary market research to the life science industry, announced today that Jason LaBonte, Ph.D., has joined the firm as President of the Insights business unit. Dr. LaBonte most recently held positions as Senior Vice President of Brand Development and Chief Operating Officer at Decision Resources Group. At MedPanel, Dr. LaBonte will be responsible for driving growth and innovation, while ensuring that the customer service the company is known for remains unparalleled.

"Jason's experience as a transformative leader and his record of successful innovation in healthcare market research were key drivers of adding him to the MedPanel team," said William Febbo, Chairman of MedPanel's Board. "Client satisfaction is our first priority, but so is offering insightful new services that keep our clients at the cutting edge of market research."

"MedPanel has a rich history of innovation; it was a pioneer in offering online panels that allowed clients to conduct focus groups in greater depth and at lower cost than live meetings," said Dr. LaBonte. "I'm excited to continue that spirit of innovation and to find new ways of leveraging MedPanel's remarkably deep medical community, our ability to recruit novel participants for cutting-edge research, and our deep relationship with clients who have trusted us with their projects for more than a decade."

Dr. LaBonte received his bachelor's degree in molecular biology from Princeton University, and his Ph.D. in virology from Harvard University. He held a number of senior positions at Decision Resources Group, including founding and leading the new products team and directing the Metabolic Disorders therapeutic area research team.  

Expansion of Services

Dr. LaBonte's appointment comes in the same year that MedPanel launched its Capital Advisors business unit. Managing Directors Hunt Henrie, who joined earlier in 2013, and Howard Brick, formerly CEO, will now focus on driving growth and development of the Capital Advisors business. Consistent with MedPanel's mission of providing essential services to the life science industry, Capital Advisors brings substantial transactional expertise and industry understanding, deep relationships with investors and corporate partners, and effectively leverages the MedPanel expert network to help clients achieve their objectives in capital raising, M&A, and strategic partnering transactions.

About MedPanel, LLC 

MedPanel, LLC, based in Cambridge, MA, provides market insights to leading corporate and financial clients in the life science industry, and corporate financial transaction advisory services to emerging life science companies. For thirteen years, its seasoned research staff has been routinely praised for designing market research that delivers the most insight for the dollar, and for its ability to recruit even the hardest-to-find respondents to participate in its studies. With dozens of research methodologies, thousands of past client engagements, and hundreds of thousands of expert physicians, nurses, patients, and hospital executives, MedPanel helps its clients make better decisions at every stage of the product life cycle, from inception of an innovative idea to post-launch and beyond. MedPanel Capital Advisors' team of experienced transaction advisors provide strategic advice and direction in guiding clients in achieving their financing, M&A, and strategic partnering objectives. Visit MedPanel at

For more information about MedPanel Insights, contact: 
Jason LaBonte 
President, MedPanel Insights 
[email protected]

For more information about MedPanel Capital Advisors, contact: 
Howard Brick 
Managing Director, MedPanel Capital Advisors 
[email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.